What is Neuronetics?
Headquartered in Malvern, Pennsylvania, Neuronetics is the industry leader in TMS technology, providing the NeuroStar Advanced Therapy system. The company distinguishes itself through an extensive portfolio of clinical evidence, positioning its technology as the gold standard for non-invasive depression treatment. By integrating advanced neuro-stimulation hardware with comprehensive practice support, Neuronetics enables healthcare providers to deliver high-efficacy mental health interventions. Their market position is fortified by a robust ecosystem that combines proprietary medical devices with ongoing clinical education and operational support for medical practices, ensuring that their technology remains at the forefront of psychiatric care.
How much funding has Neuronetics raised?
Neuronetics has raised a total of $90M across 2 funding rounds:
Series E
$30M
Debt
$60M
Series E (2021): $30M with participation from Pfizer and Polaris Partners
Debt (2023): $60M led by SLR Capital Partners, LLC
Key Investors in Neuronetics
SLR Capital Partners, LLC
SLR Capital Partners, LLC is a leading independent asset manager with significant permanent capital focused on delivering flexible debt capital solutions to U.S. based middle market businesses.
Pfizer
Pfizer Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering innovative medicines and vaccines that improve health outcomes.
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing coaching and resources for growth.
What's next for Neuronetics?
With the recent influx of capital, Neuronetics is well-positioned to accelerate its enterprise-level growth strategy. The company is expected to focus on expanding the clinical footprint of its NeuroStar platform, potentially targeting new therapeutic indications and enhancing its digital infrastructure to support a growing network of providers. By utilizing this strategic financing, Neuronetics aims to solidify its dominance in the mental health technology space, likely prioritizing operational efficiency and the scaling of its commercial reach. As the company navigates this phase of its lifecycle, the focus will remain on maintaining its clinical superiority while optimizing its financial structure to support long-term value creation for stakeholders and improved patient outcomes in the mental health sector.
See full Neuronetics company page
